Amol Akhade: What’s new and novel molecule data to look forward in ESMO24?

Amol Akhade shared a post on LinkedIn:

“What’s new and novel molecule data to look forward in ESMO24 ?

My Take

1 – Vimseltinib – oral TKI inhibitor of CSF-1R ( macrophage colony stimulating factor)
phase 3 study for rare tenosynovial giant cell tumor

2- Dazostinag ( TAK-676) -STING ( stimulator of interferon genes ) in combination with pembrolizumab- phase 1 data

3- ASP3082 – first in class KRAS G12D selective protein degrader for pancreatic cancer , CRC , NSCLC

4- STX-478 – new potent mutant selective PI3Ka inhibitor

5- Camonsertib- oral inhibitor of ATR kinase

6- Ponsegromab – first in class monoclonal AB against GF-15 for cancer cachexia

7- Zanidatamab– anti HER2 bispecific antibody with biparatropic binding- in CRC .( already got priority review by FDA for BTC )

8 – PRT3789 – first in class IV -SMARCA2 degrader in Cancers with SMARCA4 mutation.

What’s your take ? ESMO – European Society for Medical Oncology, LARVOL, Bruno Larvol.”

Source: Amol Akhade/LinkedIn

Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.